Factory Mutual Insurance Co. Cuts Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Factory Mutual Insurance Co. reduced its stake in Thermo Fisher by 15.0% in Q4, selling 14,850 shares and leaving it with 84,085 shares valued at about $48.7 million.
• Thermo Fisher beat Q4 estimates with EPS $6.57 vs. $6.45 and revenue of $12.22 billion (up 7.2% year-over-year), and analysts hold a consensus rating of "Moderate Buy" with a $632.50 price target.
• Insiders have pared holdings (CEO Marc N. Casper sold 5,000 shares for roughly $2.56 million) while the company raised its quarterly dividend to $0.47 ($1.88 annualized, ~0.4% yield); insiders now own about 0.33% of the stock.

Factory Mutual Insurance Co. lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 15.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,085 shares of the medical research company's stock after selling 14,850 shares during the quarter. Factory Mutual Insurance Co.'s holdings in Thermo Fisher Scientific were worth $48,723,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of TMO. JPL Wealth Management LLC purchased a new position in Thermo Fisher Scientific in the third quarter worth $28,000. Highline Wealth Partners LLC raised its position in Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock worth $29,000 after acquiring an additional 33 shares in the last quarter. Beacon Financial Strategies CORP purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $29,000. Olistico Wealth LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $29,000. Finally, Capital A Wealth Management LLC raised its position in Thermo Fisher Scientific by 825.0% in the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock worth $30,000 after acquiring an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on TMO shares. UBS Group reiterated a "neutral" rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Barclays raised their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, January 30th. Robert W. Baird set a $653.00 price target on Thermo Fisher Scientific in a research report on Friday, January 30th. Evercore restated an "outperform" rating and issued a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $632.50.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the firm's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president directly owned 20,752 shares in the company, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 0.8%

Thermo Fisher Scientific stock opened at $496.34 on Friday. The stock has a market cap of $184.45 billion, a PE ratio of 27.98, a P/E/G ratio of 2.68 and a beta of 0.97. The stock has a 50-day moving average price of $505.33 and a 200 day moving average price of $548.30. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping analysts' consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm had revenue of $12.22 billion during the quarter, compared to analysts' expectations of $11.95 billion. During the same quarter last year, the business posted $6.10 EPS. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio is 10.60%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.